Novel Therapy Partners Emerge in Melanoma Research

Anita T. Shaffer @Shaffer1
Published: Tuesday, Jul 18, 2017
Jessie Villanueva, PhD

Jessie Villanueva, PhD

A novel combination therapy aimed at 2 processes implicated in NRAS-mutant melanoma has displayed promising activity in preclinical investigations, signaling an avenue of exploration for a new therapeutic approach for patients who currently have few options.


Figure A. RAS Signaling and Downstream Targets2

RAS Signaling and Downstream Targets
There are no therapies targeting NRAS mutations, and this constitutes an urgent, unmet need for patients with melanoma, said Villanueva. “NRAS-mutant tumors are extremely aggressive,” she said. “They rapidly metastasize to the lymph nodes, glands, and other organs.”


Figure B. BET Inhibitors at Work4

BET Inhibitors at Work
As with other anticancer strategies, researchers found that the inhibitors were not effective as monotherapy but showed impressive preclinical activity when paired and used against NRAS-mutant melanoma with high BRD4 expression. “Targeting a single pathway or a single oncogene doesn’t really lead us to effective responses,” noted Villanueva.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication